Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance

被引:94
|
作者
Hu, Yaomin [1 ]
Liu, Wei [1 ]
Chen, Yawen [1 ]
Zhang, Ming [1 ]
Wang, Lihua [1 ]
Zhou, Huan [1 ]
Wu, Peihong [1 ]
Teng, Xiangyu [1 ]
Dong, Ying [1 ]
Zhou, Jia Wen [1 ]
Xu, Hua [1 ]
Zheng, Jun [1 ]
Li, Shengxian [1 ]
Tao, Tao [1 ]
Hu, Yumei [1 ]
Jia, Yun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Dept Endocrinol, Shanghai 200127, Peoples R China
关键词
Oral glucose tolerance test; Glycated hemoglobin A1c; Diabetes; Impaired glucose tolerance; Screening; HBA(1C) LEVELS; TESTS; RISK; HYPERGLYCEMIA; INDIVIDUALS; MELLITUS; HBA1C;
D O I
10.1007/s00592-009-0143-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study is to assess the validity of combined use of fasting plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) as screening tests for diabetes and impaired glucose tolerance (IGT) in high-risk subjects. A total of 2,298 subjects were included. All subjects underwent a 75-g oral glucose tolerance test (OGTT) and HbA1c measurement. Receiver operating characteristic curve (ROC curve) analysis was used to examine the sensitivity and specificity of FPG and HbA1c for detecting diabetes and IGT, which was defined according to the 1999 World Health Organization (WHO) criteria. (1) Based on the ROC curve, the optimal cut point of FPG related to diabetes diagnosed by OGTT was 6.1 mmol/l that was associated with a sensitivity and specificity of 81.5 and 81.0%, respectively; The optimal cut point of HbA1c related to diabetes diagnosed by OGTT was 6.1%, which was associated with a sensitivity and specificity of 81.0 and 81.0%, respectively; The screening model using FPG a parts per thousand yen 6.1 mmol/l or HbA1c a parts per thousand yen 6.1% had sensitivity of 96.5% for detecting undiagnosed diabetes; the screening model using FPG a parts per thousand yen 6.1 mmol/l and HbA1c a parts per thousand yen 6.1% had specificity of 96.3% for detecting undiagnosed diabetes. (2) Based on the ROC curve, the optimal cut point of FPG related to IGT diagnosed by OGTT was 5.6 mmol/l that was associated with a sensitivity and specificity of 64.1 and 65.4%, respectively; The optimal cut point of HbA1c related to IGT diagnosed by OGTT was 5.6%, which was associated with a sensitivity and specificity of 66.2 and 51.0%, respectively; The screening model using FPG a parts per thousand yen 5.6 mmol/l or HbA1c a parts per thousand yen 5.6% had sensitivity of 87.9% for detecting undiagnosed IGT; The screening model using FPG a parts per thousand yen 5.6 mmol/l and HbA1c a parts per thousand yen 5.6% had specificity of 82.4% for detecting undiagnosed IGT. Compared with FPG or HbA1c alone, the simultaneous measurement of FPG and HbA1c (FPG and/or HbA1C) might be a more sensitive and specific screening tool for identifying high-risk individuals with diabetes and IGT at an early stage.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 50 条
  • [31] Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening
    Torimoto, Keiichi
    Okada, Yosuke
    Tanaka, Yoshiya
    Matsuoka, Atsuko
    Hirota, Yushi
    Ogawa, Wataru
    Saisho, Yoshifumi
    Kurihara, Isao
    Itoh, Hiroshi
    Inada, Shinya
    Koga, Masafumi
    ENDOCRINE JOURNAL, 2020, 67 (05) : 509 - 513
  • [32] Detection of Diabetes Mellitus and Pre-Diabetes with A1C, Fasting Plasma Glucose and Oral Glucose Tolerance Test. A1c Based Screening May Be More Diagnostic Test for Diabetes Mellitus
    Niflioglu, Mehmet Ozgur
    Bahceci, Mithat
    Aslan, Sakine Leyla
    Topcugil, Fusun
    Tutuncuoglu, Aliye Pelin
    DIABETES, 2011, 60 : A647 - A647
  • [33] Applicability of a combination of hemoglobin A1c and fasting plasma glucose in population-based prediabetes screening
    Okosun, Ike S.
    Davis-Smith, Monique
    Seale, J. Paul
    Ngulefac, John
    JOURNAL OF DIABETES, 2012, 4 (04) : 407 - 416
  • [34] Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening
    Ben Schöttker
    Elke Raum
    Dietrich Rothenbacher
    Heiko Müller
    Hermann Brenner
    European Journal of Epidemiology, 2011, 26 : 779 - 787
  • [35] Renal Hyperfiltration in Prediabetes Confirmed by Fasting Plasma Glucose and Hemoglobin A1c
    Okada, Rieko
    Wakai, Kenji
    Naito, Mariko
    Morita, Emi
    Kawai, Sayo
    Yin, Guang
    Ozawa, Noriyo
    Furuta, Masatoshi
    Koyama, Erina
    Tsuchiya, Rumi
    Kouno, Noriko
    Hamajima, Nobuyuki
    RENAL FAILURE, 2012, 34 (09) : 1084 - 1090
  • [36] Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening
    Schoettker, Ben
    Raum, Elke
    Rothenbacher, Dietrich
    Mueller, Heiko
    Brenner, Hermann
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2011, 26 (10) : 779 - 787
  • [37] Risks of Diabetic Nephropathy with Variation in Hemoglobin A1c and Fasting Plasma Glucose
    Lin, Cheng-Chieh
    Chen, Ching-Chu
    Chen, Fei-Na
    Li, Chia-Ing
    Liu, Chiu-Shong
    Lin, Wen-Yuan
    Yang, Sing-Yu
    Lee, Cheng-Chun
    Li, Tsai-Chung
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (11): : 1017.e1 - 1017.e10
  • [38] Noninvasive type 2 diabetes screening - Superior or sensitivity to fasting plasma glucose and A1C
    Maynard, John D.
    Nguyen, Catriona M.
    Rohrscheib, Mark
    Ediger, Marwood N.
    Way, Jeffrey F.
    DIABETES CARE, 2007, 30 (05) : 1120 - 1124
  • [39] Associations of glycated hemoglobin A1c and glycated albumin with subclinical atherosclerosis in the Chinese population with impaired glucose regulation
    Ma, Xiaojing
    Shen, Yun
    Hu, Xiang
    Su, Hang
    Hao, Yaping
    Luo, Yuqi
    Tang, Junling
    Zhou, Jian
    Bao, Yuqian
    Jia, Weiping
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S147 - S147
  • [40] Validity of glycated hemoglobin in diagnostic of dysglycemia in patients with impaired fasting glucose respect to the oral glucose tolerance test
    Santos-Lozano, J. M.
    Jimenez, Md. C.
    Angel-Lugo, A.
    Gomez, A. M.
    Vilches-Arenas, A.
    Rivera-Benitez, I.
    Garcia-Corte, F. J.
    Ortega-Calvo, M.
    Toro-Cortes, C.
    Lapetra, J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2018, 48 : 180 - 180